Pandion Therapeutics Inc

Pandion Therapeutics — Investor Presentation (January 2021)

15 slides from Pandion Therapeutics's investor presentation, Jan 4, 2021

  1. Slide 1: Pandion Therapeutics January 2021

    Slide 1: Pandion Therapeutics January 2021

    Nasdaq: pand January 2021 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Company’s product candidates and the timing of availabilit

  3. Slide 3: Top-Line Data from Phase 1a Clinical Trial of PT101

    Slide 3: Top-Line Data from Phase 1a Clinical Trial of PT101

    Phase 1a single dose, randomized, blinded clinical trial in 56 healthy volunteers PT101 was well-tolerated; no serious adverse events observed PT101 selectively expanded total regulatory T cells (Treg) to levels exceeding those associated with clinical benefit in third-party clinical trials of low-d

  4. Slide 4: Tregs Play a Key Role in Immune Homeostasis

    Slide 4: Tregs Play a Key Role in Immune Homeostasis

    Regulate multiple immune cells Involved in tissue repair and regeneration Critical for self-tolerance Defects cause multi-organ inflammation Dysfunction associated with IBD, SLE, MS, T1D, other diseases Multiple third-party clinical trials suggest Treg expansion with IL-2 can benefit multiple autoim

  5. Slide 5: Low Dose IL-2 as a Strategy for Activating Tregs

    Slide 5: Low Dose IL-2 as a Strategy for Activating Tregs

    Low Dose IL-2 as a Strategy for Activating Tregs IL-2 critical growth factor for all T cells Tregs have high sensitivity for IL-2 due to constitutive expression of IL-2Rαβγ trimer Low-dose IL-2 treatment has shown clinical benefit in multiple autoimmune diseases High Dose IL-2 Pro-inflammatory for o

  6. Slide 6: Academic Data on Low Dose IL-2 Support PT101 Mechanism

    Slide 6: Academic Data on Low Dose IL-2 Support PT101 Mechanism

    Academic Data on Low Dose IL-2* Support PT101 Mechanism Dose A Dose B Dose C # of Patients 4 15 5 Aldesleukin Dose 106 IU/m2/d** 0.3 1.0 1.5 ≥2x Treg Expansion*** % of pts 50% 100% 100% and Tconv activation Clinical Response Rate week 8 25% 60% 0% Clinical Remission Rate week 8 25% 27% 0% *Aldesleuk

  7. Slide 7: Optimization and Selection of PT101

    Slide 7: Optimization and Selection of PT101

    Optimization and Selection of PT101 Selectivity Enhance with structure-based engineering Fc Fusion Best TALON format for Treg selectivity 1Reduce IL-2Rβ Affinity 2Increase IL-2Rα Affinity 3Optimize Format IL-2Rb IL-2Ra IL-2Rg N88D PT101 IL-2 Mutein N88D Start with best known mutation for Treg select

  8. Slide 8: PT101 Selectively Activates Tregs vs Tconv and NK Cells

    Slide 8: PT101 Selectively Activates Tregs vs Tconv and NK Cells

    Activated immune cells PT101 is selective for Tregs IL-2Rβγ PT101 Treg IL-2Rβγ IL-2Rα Tconv PT101 activates and expands Tregs NK Cells PT101 Selectively Activates Tregs vs Tconv and NK Cells PT101 Concentration Cellular Activation (%) PT101 selectively activates Tregs due to constitutive expression

  9. Slide 9: PT101 Phase 1a Trial Design

    Slide 9: PT101 Phase 1a Trial Design

    PT101 Phase 1a Trial Design *PK = pharmacokinetics; PD = pharmacodynamics Design Phase 1a Single Ascending Dose Study Blinded; randomized design Single site; dedicated Phase 1 unit 56 healthy volunteers across 7 cohorts 8 subjects per cohort (6 PT101 : 2 placebo) Endpoints Safety, Tolerability, and

  10. Slide 10: PT101 was Well Tolerated; No Serious AEs Observed

    Slide 10: PT101 was Well Tolerated; No Serious AEs Observed

    No serious AEs, deaths, dose-limiting toxicity, or early study discontinuation No clinically important changes in vital signs or ECGs All AEs were Grade 1 or 2, mild to moderate, and self-limited Some subjects had a transient elevation in eosinophils that were self-limited, not considered adverse, a

  11. Slide 11: PT101 Expanded Total Tregs in Healthy Volunteers

    Slide 11: PT101 Expanded Total Tregs in Healthy Volunteers

    PT101 Expanded Total Tregs in Healthy Volunteers Mean Maximum Expansion Placebo 1 mg 3.5 mg 5 mg 7.5 mg 10 mg Fold Change PT101 expanded total Tregs with up to a mean maximum fold change of 3.6 ≥2-fold total Treg expansion associated with clinical benefit in third-party clinical trials in multiple a

  12. Slide 12: PT101 Markedly Expanded the CD25bright Treg Subset

    Slide 12: PT101 Markedly Expanded the CD25bright Treg Subset

    PT101 Markedly Expanded the CD25bright Treg Subset Mean Maximum Expansion PT101 expanded the CD25bright Treg subset with up to a mean maximum fold change of 72.5 It has been reported that CD25bright Tregs may be a more active subset of Tregs with enhanced immune regulatory function Placebo 1 mg 3.5

  13. Slide 13: Robust Treg Response Rate Observed with PT101

    Slide 13: Robust Treg Response Rate Observed with PT101

    Robust Treg Response Rate Observed with PT101 Fold Change Placebo (n=14) 1 mg (n=6) 3.5 mg (n=12) 5 mg (n=12) 7.5 mg (n=6) 10 mg (n=6) 2x or greater 7% 33% 83% 83% 100% 100% 3x or greater 0% 0% 58% 75% 33% 50% 4x or greater 0% 0% 24% 42% 33% 17% More than 80% of subjects achieved 2-fold or greater t

  14. Slide 14: PT101 Maintained Treg Selectivity Throughout Dose Range

    Slide 14: PT101 Maintained Treg Selectivity Throughout Dose Range

    PT101 Maintained Treg Selectivity Throughout Dose Range Values are mean (SEM) 50%tile and 95%tile are derived from analysis of 129 subjects’ Day -10 screening samples in Cohorts 1-7 Common datapoints for cohorts 1-7 are shown; data was also collected from cohorts 4-7 on Days 6, 10, 12, and 22 (not s

  15. Slide 15: Conclusion

    Slide 15: Conclusion

    PT101 was well-tolerated; no serious adverse events observed PT101 selectively expanded total Tregs to levels exceeding those associated with clinical benefit in third-party clinical trials of low-dose IL-2 At doses 3.5 mg and above, >80% of subjects achieved 2-fold or greater Treg expansion Mean ma

Source: SEC EDGAR · 8-K filed Jan 4, 2021